US Congress House Bill 3731 (Prior Session Legislation)

---

Spectrum: Bipartisan Bill
Status: Introduced on October 9 2015 - 25% progression, died in committee
Action: 2015-10-16 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]

RaD Fund Act Rare Disease Fund Act This bill requires the National Institutes of Health (NIH) to organize the Rare Disease Therapeutics Corporation to purchase rights to, fund the development of, and sell ownership interests in drugs, biological products, and medical devices for rare diseases. The NIH must sell stock in the corporation to investors as soon as practicable. The corporation and the NIH may enter into an agreement under which the NIH maintains an ownership interest in the corporation in exchange for providing the corporation with intellectual property or other assistance. The corporation is prohibited from paying dividends on its stock. The corporation must sell its interest in a rare disease therapy prior to the therapy entering large-scale clinical trials. The corporation must issue bonds guaranteed by the United States and may issue bonds backed by the corporation. For purposes of securities laws, the securities of the corporation are not issued or guaranteed by the federal government. The bill establishes within the NIH the Rare Disease Therapeutics Corporation Science Advisory Council to advise the corporation on the purchase, sale, and development of rare disease therapies.

RaD Fund Act Rare Disease Fund Act

Rep. Juan Vargas [D-CA]

Rep. Thomas Rooney [R-FL]

Date	Chamber	Action
2015-10-16	House	Referred to the Subcommittee on Health.
2015-10-09	House	Referred to the House Committee on Energy and Commerce.
2015-10-09	House	Introduced in House

Type	Source
Summary	https://www.congress.gov/bill/114th-congress/house-bill/3731/all-info
Text	https://www.congress.gov/114/bills/hr3731/BILLS-114hr3731ih.pdf